Pain pp 1223-1226 | Cite as

Polymyalgia Rheumatica

  • Phillip Telefus
  • Samuel SamuelEmail author


Polymaglia Rheumatica is a chronic inflammatory condition that classically affects proximal muscles and joints as the result of pro-inflammatory cytokines in the setting of immune system imbalance. Presented are details of clinic presentations, diagnostic tools, differential diagnoses and treatment regimens.


Polymyalgia rheumatica Giant-cell arteritis Glucocorticoids 


  1. 1.
    Caylor T, Perkins A. Recognition of polymyalgia rheumatia and giant cell arteritis. Am Fam Physician. 2013;88(10):676–84.PubMedGoogle Scholar
  2. 2.
    Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pre-treatemnt characteristics and tocilizumab therapy. Clin Rheumatol. 2014;35:1367–75.CrossRefGoogle Scholar
  3. 3.
    Weyand C, Goronzy J. Giant-cell arteritis and polymaglia rheumatica. N Engl J Med. 2014;371(1):50–7.CrossRefGoogle Scholar
  4. 4.
    Kermani T, Warrington K. Advances and challenges in the diagnosis and treatment of polymalgia rheumatica. Ther Adv Musculoskelet Dis. 2015;6(1):8–19.CrossRefGoogle Scholar
  5. 5.
    Dasgupta B, Cimmino M, Maradit-Kremers H, Schmidt W, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012b;71:484–92.CrossRefGoogle Scholar
  6. 6.
    Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–90.CrossRefGoogle Scholar
  7. 7.
    Dejaco C, Singh Y. 2015 Recommendations for the Management of Polymyalgia Rheumatica. Arthritis and Rheumatology. 2016;67(10):2569–80.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pain Management DepartmentCleveland ClinicClevelandUSA

Personalised recommendations